Clinical Cardiology

View the latest content related to this topic

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

The trends were in the right direction, including a significant 30% reduction in HF hospitalization, but missed superiority for MACE.

Michael O'Riordan

September 24, 2020

Slides

See all

Presentation

ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation

ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation

ACC 2020

A Randomized Controlled Trial Evaluating the Efficacy and Safety of E-Cigarettes for Smoking Cessation

Presenter: Mark Eisenberg

March 30, 2020

Presentation

ACC 2020

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Presenter: Deepal L. Bhatt

March 30, 2020

Presentation

ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

News

See all

News • Interventional

Making Sense of MI: EXCEL and SYNTAX Tackle Event Definitions

By Michael O'Riordan

September 28, 2020

News

COVID-19: TCTMD’s Daily Dispatch for September 28

By Shelley Wood

September 28, 2020

News

Women With Prior SCAD Not Always at Risk of Recurrence in Pregnancy

By Caitlin E. Cox

September 25, 2020

News • Interventional

Among US Women, Awareness of CVD’s Threat Has Declined

By L.A. McKeown

September 25, 2020

News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

By Michael O'Riordan

September 24, 2020

CTO 2021

February 18

February 19, 2021

TCT Connect 2020

October 14

October 18, 2020

TVT Connect 2020

June 18

June 28, 2020

PCR e-Course 2020

June 25

June 27, 2020

Videos on This Topic

See all

REGISTER for free or LOG IN to view this content

February 24, 2020

Advertisement

Clinical Cardiology

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Slides

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

A Randomized Controlled Trial Evaluating the Efficacy and Safety of E-Cigarettes for Smoking Cessation

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

News

Making Sense of MI: EXCEL and SYNTAX Tackle Event Definitions

COVID-19: TCTMD’s Daily Dispatch for September 28

Women With Prior SCAD Not Always at Risk of Recurrence in Pregnancy

Among US Women, Awareness of CVD’s Threat Has Declined

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

More on This Topic

Upcoming Conferences

CTO 2021

TCT Connect 2020

Conference Coverage

TVT Connect 2020

PCR e-Course 2020

Videos on This Topic

REGISTER for free or LOG IN to view this content

Advertisement

Advertisement

Clinical Cardiology

Slides

News

More on This Topic

Upcoming Conferences

Conference Coverage

Videos on This Topic

REGISTER for free or LOG IN to view this content

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content